Enterococci, butyric acid have excellent diagnostic efficacy in acute myeloid leukemia.
The purpose of this study was to determine whether newly diagnosed AML patients had changed their intestinal microbes and metabolites. Do these altered metabolites and microbiota have the potential to be used as biomarkers to help diagnose diseases? Notably, the intestinal microbiota and metabolites of AML patients showed notable structural and quantitative alterations at the time of first diagnosis. Beneficial bacteria including Faecalibacterium, Collinsella, Lacticaseibacillus, and Roseburia—as well as butyric acid and acetic acid—were considerably reduced in newly diagnosed AML patients, but Enterococcus and Lactobacillus, especially Enterococcus, were found to be enriched. Subsequent investigation indicated that Enterococcus was a very potential intestinal marker which had a strong negative correlation with the levels of acetic and butyric acid. Crucially, assays for AML identification showed that Enterococcus, butyric acid, and acetic acid had excellent diagnostic effectiveness. Patients' colonizing Enterococcus strains were isolated for pathogen investigation, which revealed that these bacteria have several strong virulence and multiple drug resistance genes characteristics. Thus, we speculate that Enterococcus plays a function for the development of AML as well as its progression.